Experimental eye drops for GVHD dry eye show early promise but trial stops short
NCT ID NCT06495307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new eye drop (rhPRG4) in 3 adults with moderate to severe dry eye from chronic graft-versus-host disease (GVHD), a complication of bone marrow transplants. The goal was to see if the drops safely improve dryness and eye surface damage. The trial was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
3 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Mar 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Diagnosis and Main Criteria for Inclusion: All to be queried and checked at the screening visit (V1): 1. Subjects 18 years of age or older; 2. Subjects diagnosed with oGVHD for at least 3 months (current use of artificial tears for the treatment of GVHD); 3. VAS Eye Dryness (100-point scale) score ≥ 60 mm; 4. Tear Osmolarity ≥ 312 in either eye; 5. Corneal staining score with fluorescein ≥ 2 using the Oxford scale in the worst performing eye; staining must include quadrants beyond only inferior or superior staining; 6. Only subjects who satisfy all Informed Consent requirements may be included in the study. Exclusion Criteria: Diagnosis and Main Criteria for Exclusion: 1. Evidence of an active ocular infection in either eye; 2. History or presence of ocular surface disorders not related to oGVHD in either eye, including but not limited to significant conjunctivochalasis, superior limbic keratoconjunctivitis, limbal stem cell deficiency, allergic conjunctivitis, giant papillary conjunctivitis, atopic keratoconjunctivitis, anterior basement membrane dystrophies, neurotrophic keratitis, corneal dystrophy, exposure keratitis and moderate to severe blepharitis; 3. History of any ocular surgery (including laser or refractive surgical procedures) in either eye within 90 days before study enrollment. Ocular surgery will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period; 4. Initiation of new therapeutic modalities within 30 days of recruitment; 5. Artificial rescue tears are allowed as long as they are recorded in a diary; 6. Known hypersensitivity to one of the components of the study or procedural medications; 7. Participation in another clinical study at the same time as the present study or within 60 days of screening/baseline visit; 8. History of drug, medication or alcohol abuse or addiction; 9. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions: 1. are currently pregnant or, 2. have a positive result on the urine pregnancy test at the Screening/Baseline Visit or, 3. intend to become pregnant during the entire course of and 30 days after the study treatment periods, or, 4. are breast-feeding or, 5. not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods, during the entire course of and 30 days after the study treatment periods.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ocular graft versus host disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OTA
Brisbane, Queensland, Australia
-
Sydney Eye Hospital
Sydney, New South Wales, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.